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We summarize here the studies examining the association between thyroid function and cognitive performance from an aging
perspective. The available data suggest that there may be a continuum in which cognitive dysfunction can result from increased
or decreased concentrations of thyroid hormones. Clinical and subclinical hypothyroidism as well as hyperthyroidism in middle-
aged and elderly adults are both associated with decreased cognitive functioning, especially memory, visuospatial organization,
attention, and reaction time. Mild variations of thyroid function, even within normal limits, can have signiﬁcant consequences for
cognitive function in theelderly. Diﬀerent cognitive deﬁcits possiblyrelatedtothyroidfailuredonot necessarily followaconsistent
pattern, and L-thyroxine treatment may not always completely restore normal functioning in patients with hypothyroidism. There
is little or no consensus in the literature regarding how thyroid function is associated with cognitive performance in the elderly.
Copyright © 2008 M. E. B´ egin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Adequate thyroid function is essential for normal develop-
ment and retention of cognitive function throughout life.
The association between thyroid hormones and cognition
has been recognized since the demonstration that cretinism
stems from iodine and thyroid deﬁciencies. Low thyroid
function at any age causes cognition to deteriorate because
hypothyroidism prevents the brain from adequately sustain-
ing the energy (glucose)-consuming processes needed for
neurotransmission, memory, and other higher brain func-
tions. Low brain uptake of glucose is commonly associated
withdeterioratingcognitionandAlzheimer’sdiseaseandcan
be present decades before clinical evidence of Alzheimer’s
disease occurs [1, 2]. Brain hypometabolism therefore
appears to be a precursor lesion increasing the risk of at
leastsomeformsofcognitivedecline.Sincethyroidhormone
concentrations change with age and since cognitive decline
is often concomitant with aging, physiological changes in
thyroid function might be causally related to changes in
cognition during normal aging.
Mental activities involved in the acquisition, storage,
retrieval, and use of information are referred to here by
the term “cognition” [3, 4]. Manifestations of cognitive
behavior are achieved through the integration of a variety
of processes and activities such as perception, imagery,
memory, reasoning, problem solving, decision-making, and
language. A summary of cognitive measurements used in
thyroid function studies are shown in Table 1.
Thyroid function has been measured as serum concen-
trations of thyroid-stimulating hormone (TSH) or thyroid
hormones (total or free thyroxine [T4], total or free tri-
iodothyronine [T3], or T3 resin uptake). Most studies
reported TSH, since it is very reproducible and is commonly
believed to be the best marker of thyroid status, in combina-
tion with one or two thyroid hormones measurements.
Our aim here is to summarize the growing literature on
the relationship between cognitive performance and thyroid
function from an aging perspective. Several studies have
been carried out to investigate whether thyroid function can
explain the substantial individual diﬀerences in cognitive
performance of older individuals. The characteristics of the2 Current Gerontology and Geriatrics Research
Table 1: Cognitive domains and measures (AN: animal naming; CC: cube copying; CoS: Corsi’s span; CST: concept shifting test; CVMT:
continuous visual memory test; d2: d2 test; DRS: dementia rating scale; DS: digit spans forward and backward of WAIS-R; FMT: Milner
facialmemorytest;FR:ﬁgurerotationfromtheSchaie-Thurstoneadultmentalabilitiestest;GNG:Go-NoGo;HT:Hoopertest;IPALT:Inglis
paired associates learning test; LDC: letter digit coding test; LMN: Luria m’s and n’s; LW: list of words; MHV: Mill Hill Vocabulary Scale;
MMSE:Mini-MentalStateExamination;MMMSE:ModiﬁedMini-MentalStateExamination;OR:oralreading;PASAT:pacedauditoryserial
addition task; PM: Porteus maze; RBP: Rivermead behavioral proﬁle; RCFT: Rey-Osterrieth complex ﬁgure test; RPM: raven progressive
matrices test; RW: Rey’s words immediate and delayed recall; ScT: scribble test; SDMT: symbol digit modalities test; SRT: selective reminding
test (Buschke); ST: Stroop test; SVT: Shipley Vocabulary test; TMTA&B: trail making test A and B; WAIS: Wechsler adult intelligence scale;
WAIS-R: Wechsler adult intelligence scale-revised; WD: word discrimination; WFT: word ﬂuency test; WLT: word learning task; WMS:
Wechsler memory scale; ZVT: Zahlenverbindungstest).
Cognitive domain Measures
General intelligence RPM, MHV, SVT, WAIS, WAIS-R, DRS
Attention and concentration PASAT, TMTA&B, SDMT, ST, DS, CST, d2,
M e m o r y W M S ,C V M T ,F M T ,R C F T ,S R T ,I P A L T ,D S ,W L T ,L W ,R B P
Visuospatial organization WAIS-R, CC, TMT(Part A), FR, HT, ScT, CoS
Language WFT, AN, WD, RW, OR
Executive function GNG, WFT, LMN, PM, TMT
Global cognition MMSE, MMMSE
Cognitive or psychomotor speed WAIS-R, TMT(Part A), WFT, LDC, ZVT
association between thyroid function and cognition will be
described ﬁrst in healthy euthyroid individuals and then
in patients with diﬀerent degrees of hypothyroidism or
hyperthyroidism.
2. Age-Related Changes inCognition
and Thyroid Function
Several changes in thyroid function occur during aging.
Normal aging is associated with changes in thyroid hormone
production and metabolism [5, 6]. Secretion of T4 and
T3 is reduced in the healthy elderly (61–90 years old),
but serum concentrations of total and free T4 remain
relatively unchanged because T4 degradation is also reduced
in the elderly. Circulating total and free T3 concentrations
demonstrate a clear, age-dependent decline because of both
reduced secretion and reduced peripheral conversion from
T4. Serum reverse T3 (rT3) seems to increase with age. The
decrease in serum T3 levels together with the increase in
serum rT3 may indicate a decrease in peripheral hepatic
metabolism of iodothyronines during aging.
Data on TSH changes during healthy aging are equivocal:
some studies show unchanged TSH concentrations while
others show mildly increased TSH in both men and women.
After excluding subjects with subclinical hypothyroidism,
the data suggest that TSH secretion may actually be slightly
decreased in healthy elderly individuals [5]. A decline in
both the circadian patterns and maximal nocturnal levels
contributes in decreasing TSH levels in the elderly [5, 7].
The evaluation of normal thyroid function in the elderly
is commonly confounded by subclinical hypothyroidism, by
an increased prevalence of acute or chronic nonthyroidal
illness, by drug use, and by nutritional deﬁciencies [6]. Some
studies on healthy elderly subjects selected by strict criteria
to exclude coexisting diseases suggest that an age-dependent
decline in thyroid function is at least partially independent
of nonthyroidal illnesses, particularly in the oldest old (>85
years) population [5, 8]. In the healthy elderly, thyroid
function appears to be well preserved until the eighth decade
of life, and a reduction of serum free T3 is only observed in
the extremely old (100–110 years) [8].
An increased risk of declining cognitive function with
aging is well-known, especially with regard to working
memory, information processing speed, and long-term
memory[4,9–13].Workingmemoryisanessentialcognitive
resource whereby information is temporarily stored and
made readily available to the various processes carrying
on a speciﬁc task. Diﬀerences in cognitive eﬃcacy can be
related to discrepancies in working memory, including those
presumably caused by normal or pathological aging [4].
Since it plays such a central role, alterations of working
memory can have an eﬀect on language processing, problem
solving, decision-making, and encoding or retrieving of
information in long-term memory.
Information processing speed is also an important
resource, deﬁned by the time parameters of a speciﬁc
cognitive task. Shortest latencies are usually associated with
youthandbetterperformances.Thelabel“cognitiveslowing”
has been applied to age-related increases in those latencies,
which in turn can be held responsible for many aspects of
declining cognitive functioning [4].
Eﬃciency of the three main aspects of long term
memory—encoding, storage, and retrieval—declines over
time [10]. A possible explanation could be that the elderly
spontaneously deploy less eﬀort at the time of exposure to
properly encode information, thereby diminishing storage
capacity and undermining subsequent retrieval attempts.
This might be the reason why, for the elderly, retrieval tasks
are especially diﬃcult when summoned out of context [4].
An important decrease in mnesic performances has been
observed, usually correlating with the complexity of the
material, using either verbal or spatial stimuli, as well as
declarative or procedural knowledge.Current Gerontology and Geriatrics Research 3
Table 2: Relation between thyroid function and cognition in euthyroid elderly (>65 years old) (A: attention; BD: block design of WAIS-R;
CST: concept shifting test; DRS: dementia rating scale; DS: digit span forward and backward of WAIS-R; FR: ﬁgure rotation; FT3: free T3;
G: global; LDC: letter digit coding test; LW: list of words; M: memory; MMSE: Mini-Mental State Examination; MRT: median reaction time
tests; NS: not speciﬁed; NTI: nonthyroidal illnesses; O: orientation; PS: psychomotor speed; RBP: Rivermead behavioral proﬁle; ST: Stroop
test; TMTA&B: trail making test A and B; TSH: thyroid stimulating hormone; TT4: total T4; VF: verbal ﬂuency; VSA: visuospatial ability;
WAIS-R: Wechsler adult intelligence scale-revised; WLT: word learning task).
Source Age, years Gender Population health
status
Altered cognitive
domain
Thyroid function
indicator Measures
mean range women men N
van Boxtel et al. [14] 60 49–71 NS NS 120 Healthy + hypo M TSH WLT, CST, ST
Prinz et al. [15] 72 65–78 0 44 44 Healthy G, VF TT4
WAIS-R, DRS, VF,
FR, RBP, MMSE,
MRT
Volpato et al. [16] 72 75–80 464 0 464 Heathy + NTI O, M TT4 MMSE
Wahlin et al. [17] 84 75–96 159 41 200 Healthy M TSH
DS-WAIS-R, LW,
TMTA&B, BD
Wahlin et al. [18] NS 75–93 39 6 45 Healthy VF, VSA→ MT S H RT, BD, VF, TMTA&B
Gussekloo et al. [19] 85–89 369 189 558 Mixed G, A, M, PS FT3 MMSE, ST, LDC,
WLT
However, not all aspects of memory are equally aﬀected
with age [9]. For example, organization of long-term
memory and priming of the information it contains remain
relatively intact. Implicit inductive reasoning also seems to
be well preserved, compared to explicit learning capacity.
Broadly speaking, episodic memory, being the long-term
memory concerned with items associated with a speciﬁc
context in space and time, is generally more aﬀected
than semantic memory, which is the long-term memory
concerned with general knowledge and values which have
become quite independent of their acquisition context.
3.CognitiveDeclineinHealthy
Euthyroid Elderly
Table 2 shows relevant characteristics of ﬁve studies that
sought to establish whether reduced thyroid function
adversely aﬀects cognitive function in healthy euthyroid
individuals during aging. In a cross-sectional study involving
a random sample of individuals aged from 49 to 71 years
(mean age of 60 years), van Boxtel et al. [14] found that
higher levels of TSH predicted lower levels of memory
performance but that this association was not signiﬁcant
after correcting for mood status and the presence of possible
thyroid dysfunction. Prinz et al. [15] suggested that total
T4 levels and possibly free T4, but not total T3 nor
TSH, were signiﬁcantly associated with better cognitive
performance in euthyroid men aged 65–78 years (mean
72 years) who had no overt physical or mental illness.
In physically impaired 75–80-years-old euthyroid women,
Volpato et al. [16] demonstrated that lower total T4 levels,
(still within the normal range), but not TSH, were associated
with a greater risk of decline in components of episodic
memory over a 3-year period. Women with serum total
T4 concentrations of 4.5–6.5μg/dL had a twofold risk of
cognitive decline compared to women with serum total
T4 concentrations of 8.1–12.5μg/dL. No association was
found between baseline TSH level and change in cognitive
function. These results were not substantially modiﬁed
after adjustment for potential confounders including age,
race, level of education, medication use, and presence of
nonthyroidal illnesses.
Conversely, from a cross-sectional study of euthyroid
very old women and men 75–96 years old (mean age = 84
years), Wahlin et al. [17] reported that, within the normal
r a n g e ,T S Hl e v e l sb u tn o tf r e eT 4w e r ep o s i t i v e l ya s s o c i -
ated with episodic memory performance. The eﬀects were
independent of age, educational level, and depressive mood
symptoms. No signiﬁcant eﬀects of TSH were depicted on
verbal ﬂuency, short-term memory, perceptual-motor speed,
or visuospatial functioning. From further examination of
very old women (n = 39) and men (n = 6), respectively,
Wahlin et al. [18] provided longitudinal evidence of the
impact of normal TSH variations on cognitive functioning.
Their analyses revealed that declining TSH levels within the
normal range were accompanied by a parallel decline in
verbal ﬂuency and visuospatial abilities, predicting episodic
memorydeﬁcitsaftersixyearsfollow-up.BaselineTSHlevels
did not predict future decline of cognitive functioning. Con-
versely, Gussekloo et al. [19] found that low-free T3, but not
TSH or free T4, was associated with an accelerated decline
in global cognitive function as measured by the MMSE in
an unselected general population of 558 individuals aged 85
years, of whom 85% were euthyroid, 5% were subclinically
hypothyroid, 7% were clinically hypothyroid, and 3% were
hyperthyroid, both at baseline and after a follow-up of 3.7 ±
1.4y e a r s .4 Current Gerontology and Geriatrics Research
Clearly, the results from these studies are disparate and
conﬂicting as to which indicator of thyroid function is
the most relevant marker of speciﬁc cognitive function,
and which domain of cognitive functioning is primarily
aﬀected by thyroid hormonal variations. However, the over
all ﬁndings suggest that, although thyroid hormones may
have an impact on a variety of cognitive functions, only a
linktocertainmemoryfunctionshasbeensofarhighlighted.
Diﬀerences in results may be due to diﬀerences in sample
selection, age ranges, choice of cognitive tests, and to higher
TSHandcognitivevariabilitywithincreasingageandlimited
number of thyroid function indices. More prospective follow
up studies on a well-characterized selected population of
healthy elderly are needed with repeated assessment of mul-
tiple indicators of thyroid function, ample speciﬁc cognitive
measurements, and adequate assessment of mood status.
4.CognitiveImpairmentinSubclinical
Hypothyroidism
Subclinical hypothyroidism is deﬁned as an elevated TSH
levels in the presence of normal circulating T4 and T3
concentrations plus the absence of features of clinical
hypothyroidism [20, 21]. About one-third of subclinically
hypothyroid patients present mild, nonspeciﬁc symptoms
possibly pointing to a mild hypothyroidism [22, 23]o ra
subclinical hypothyroidism, the latter being the term most
frequently used in the studies examined.
Subclinical hypothyroidism may be a predisposing factor
for cognitive impairment. Table 3 shows the results of
diﬀerent studies of cognitive impairment in subclinical
hypothyroidism in order of increasing age. Patients with
subclinicalhypothyroidismforalongtime(16±6.2months)
manifested impaired cognitive activity as evidenced by sig-
niﬁcantly longer P3 wave latency of event-related potentials
compared to healthy individuals [23]. Five cross-sectional
studies suggest that young adult patients with subclinical
hypothyroidism had mild dysfunction in learning, memory,
and selective attention. Monzani et al. [24] found memory
deﬁcits in a group of 13 women and 1 man (29 to 47 years
old) with untreated subclinical hypothyroidism compared
to 50 euthyroid control subjects. Similarly, Baldini et al.
[25] found that 19 young and middle-aged women with
subclinical hypothyroidism showed worse memory, but
no diﬀerences in scores of mental control, attention, or
visuospatial abilities compared with 17 euthyroid control
women. del Ser Quijano et al. [26] identiﬁed slower reaction
time, reduced verbal ﬂuency, and impaired visual memory
in a group of 15 young adults with subclinical hypothy-
roidism compared with a group of 15 euthyroid control
subjects. Cook et al. [27] reported that elderly patients
with subclinical hypothyroidism performed more poorly
than euthyroid individuals on measures of verbal recall as
well as on the Mini-Mental State Examination but working
memory and processing speed were unaﬀected. A decrease
in verbal ﬂuency was noted in the study of Manciet et
al. [28] in a population sample of 425 individuals (65–85
years old or older) comprising 89.7% euthyroid subjects,
4.2% with subclinical hypothyroidism, 1.9% with clinical
hypothyroidism, and 4.2% with hyperthyroidism.
In contrast, three studies failed to ﬁnd cognitive impair-
ment associated with subclinical hypothyroidism. No diﬀer-
ences were found by Osterweil et al. [29] between the 14
patients with subclinical hypothyroidism and 30 controls.
Similarly, in a group of elderly subjects aged 65–92 years,
Luboshitzky et al. [30] reported no signiﬁcant diﬀerences
in cognitive impairment measured by the Mini-Mental
State Examination in 39 untreated subclinically hypothyroid
patients compared to 570 euthyroid controls. Bono et al.
[31] provided evidence that subclinical hypothyroidism in
36 women barely aﬀected their cognitive status but may have
caused an age-related impairment of attentive functions.
The possibility of reversing some aspects of the cognitive
impairment associated with subclinical hypothyroidism has
been demonstrated after treatment with L-thyroxine. Two
single-case studies showed that L-thyroxine treatment was
associated with reversal of the cognitive impairment in
each case [32, 33]. In a larger study, Bono et al. [31] also
obtained a slight but signiﬁcant improvement of verbal
ﬂuency in 36 women with subclinical hypothyroidism after
6 months treatment with L-thyroxine but this showed
no correlation with TSH changes after treatment. Three
uncontrolledstudiesshowedimprovementsinmemoryskills
after 3 or 6 months of treatment with L-thyroxine [24, 25].
The comprehensive study of del Ser Quijano et al. [26]
revealed that L-thyroxine treatment was associated with
signiﬁcant improvements on multiple cognitive measures
including attention, memory, verbal ﬂuency, and executive
functions compared to control participants.
The eﬀects of L-thyroxine treatment were also investi-
gated in three small randomized, placebo-controlled trials.
A modest but statistically signiﬁcant improvement in a
composite memory score was obtained in patients treated
withL-thyroxinefor10monthscomparedtoplacebocontrol
patients [34]. However, the diﬀerence was small enough to
be of questionable clinical importance. Compared to the
placebo control group, Nystr¨ om et al. [35] reported that in
a 6-month double-blind, crossover study using L-thyroxine
treatment, up to 20% of patients improved their memory
scores and reaction time but only half of them also improved
their perceptual speed. Jensovsky et al. [23] found signiﬁcant
improvement of verbal, visual, and total memory scores after
the normalization of TSH level by L-thyroxine treatment for
6 months in the treated individuals compared to the control
individuals.
The interpretation of these studies is diﬃcult due to vari-
ations in both the deﬁnition and the etiology of subclinical
hypothyroidism, the presence or absence of symptoms, and
to the limited number of subjects investigated. Nevertheless,
taken together, the results suggest that evaluation and
treatment of subclinical hypothyroidism in the elderly may
bebeneﬁcialinviewofitsprevalenceanditspotentialclinical
importance. Indeed, subclinical hypothyroidism is common
with estimates ranging from 5% to 17% in the general
population, with an age-related increase to as many as 20%
of women and 9.5% of men over the age of 60 years [6, 22,
30, 36–39]. The prevalence of subclinical hypothyroidism inCurrent Gerontology and Geriatrics Research 5
Table 3: Cognitive impairment in subclinical hypothyroidism (A: attention; BMT: Bingley’s memory test; BVRT: Benton’s visual retention
test; CS: Corsi’s span forward and backward; DC: drawing copy; DSB: digit span backward; DSCT: digit symbol coding test from the WAIS-
III; DSF: digit span forward; DSS: digit symbol substitution; EF: executive functions; IFT: identical forms test of Thurstone; IST: Isaacs’
set test of verbal ﬂuency; LM: logical memory test; M: memory; MMSE: Mini-Mental State Examination; NBT: N back test; PS: perceptual
speed; RAVLT: Rey auditory verbal learning test; RF: Rey’s ﬁgure; RPM: Raven’s progressive matrices; RT: reaction time; RW: Rey’s words
immediate and delayed recall; S: speed test; ScT: Scribble test; TMTAB: trail making test A and B; VF: verbal ﬂuency; VF: verbal ﬂuency
test; WAIS: Wechsler adult intelligence scale; WFT: word ﬂuency test; WLT: word learning test; WMS: Wechsler memory scale; ZBT: Zazzo’s
barring test).
Source
Participants Impaired
cognitive
domain
Tests Treatment outcome Age, years Gender
Mean ± SD
and/or (Range)
women men N
del Ser Quijano 38 ± 9.5 12 3 15 A, M, VF, EF MMSE, WAIS, RT, BVRT,
RF, WLT, VF, TMTAB
Improvement after 6 months
et al. [26] (23–53)
Monzani 39 ± 9 13 1 14 MW M S Improvement after 6 months
et al. [24] (29–47)
Baldini 55 ± 9 19 0 19 MW M S , S c T , S Improvement after 3 months
et al. [25] (28–68)
Bono et al. [31]
52 ± 13.5 36 0 36 A, VF
MMSE, DSF, DSB, CS,
RW, TMTAB, RPM, DC,
VF
Improvement after 6 months
(31–70)
Nystr¨ om et al. [35] (51–73) 17 0 17 PS, M, S IFT, BMT, RT Improvement after 6 months
Jaeschke et al. [34]6 8 ± 9.4 28 8 36 M, PS LM, WLT, WFT, DSS,
TMT
Improvement after 10 months
Jensovsky et al. [23]6 2 ± 6.8 20 0 20 MW M S Improvement after 6 months
Manciet et al. [28] (65–85) 256 169 425 VF MMSE, BVRT, WAIS,
ZBT, IST
No treatment
Cook et al. [27]7 4 ± 3.9 NS NS 15 M,VF MMSE, RAVLT, DSCT,
NBT, DSB
No treatment
men over the age of 74 years was 16% which approaches the
21% prevalence seen in women of the same age [40].
T h ee l d e r l ym a yb em o r ev u l n e r a b l et ot h ec o g n i t i v e
eﬀects of subclinical hypothyroidism than young adults,
suggesting that diagnosis and treatment may protect the
aging brain from cognitive deterioration. However, it is
not yet certain that favorable results obtained with middle-
aged patients are predictive of favorable responses in
elderly. Furthermore, diﬀerent cognitive functions prob-
ably have varying sensitivity to hormonal or metabolic
changes. Not all the cognitive defects related to thyroid
failure are completely reversible with L-thyroxine therapy.
Additional controlled studies are required to answer these
questions.
5. CognitionDeﬁcits inClinical
Hypothyroidism
Adult clinical hypothyroidism is the result of decreased
serumlevelsofthyroidhormonesandhasavarietyofadverse
eﬀects on cognitive function [29, 41–49]. Common cogni-
tive deﬁcits observed in middle-aged clinical hypothyroid
patients include diminished general cognition, attention,
learning, memory, and psychomotor speed (see Table 4).
However, language comprehension and possibly sustained
auditory attention are less impaired than other cognitive
functionsinclinicalhypothyroidism. Whetherornotthereis
acorrelationbetweenthecognitivealterationsandthedegree
or the duration of hypothyroidism still needs to be clariﬁed.
Although L-thyroxine successfully treats low thyroid
status in the majority of hypothyroid patients, it is well
recognized that a minority of patients have persistent
symptoms. As shown in Table 4, several reports demonstrate
that treatment of hypothyroidism during 3, 6, or 10.5
months still appears to be associated with only partial
and inconsistent patterns of recovery of overall cognitive
functioning. Similarly, the study of Wekking et al. [58]
showed that cognitive defects, especially involving atten-
tion and verbal memory, persisted in a large group of
hypothyroid patients, given suﬃcient L-thyroxine treatment
over 5.5 years to normalize TSH. These results indicate
that signiﬁcant memory deﬁcit in middle-aged adults with
hypothyroidism can persist even after “adequate” thyroid
replacement.
Three studies investigated the possibility that the brain
becomes more susceptible to thyroid dysfunction in the6 Current Gerontology and Geriatrics Research
Table 4: Cognitive deﬁcits in adult clinical hypothyroidism (AN: animal naming; BD: block design of WAIS-R; BEC-96: recall and
visuoverbal recognition test; CC: cube copy; COWA: controlled oral word association; CVLT: California verbal learning test; CVMT:
continuous visual memory test; DRS: Dementia rating scale (Mattis); DS: digit symbol subtest; FMT: Milner facial memory test; GNG,: Go-
Nogo;HT:Hoopertest;IPAL:Inglispairedassociateslearning;LMN:Luriam’sandn’s;MHV:Millhillvocabularyscale;MMSE:minimental
sate examination; MMMSE: modiﬁed Mini-Mental State Examination; OAS: object assembly subsets of WAIS-R; OR: oral reading; PASAT:
paced auditory serial addition task; PM: Porteus mazes; ROCF: Rey-Osterrieth complex ﬁgure test; RPM: Raven progressive matrices test;
SDMT: symbol digit modalities test; SRT: selective reminding test (Buschke); SVT: Shipley vocabulary test; TMT(A): Trail making part A;
TMT(A,B): Trail making test parts A and B; VLT: verbal learning test ; WAIS: Wechsler adult intelligence scale; WAIS-R: Wechsler adult
intelligence scale-revised ; WD: word discrimination; WFT: word ﬂuency test; WMS: Wechsler memory scale).
Cognitive domain Source Altered Treatment outcome Measures
General intelligence
Capet et al. [43]Y e s Improvement after 6
months
WAIS-R
Mennemeier et al. [46]Y e sNot generally aﬀected WAIS-R
Haggerty et al. [45]Y e s No change after 3
months
WAIS, DRS
Crown [44]Y e s Improvement after 8
months
RPM, MHV, SVT
Attention
Miller et al. [47]N o No improvement TMT(A)
Capet et al. [43]Y e s Improvement after 6
months
TMT(A), WMS,
Mennemeier et al. [46]N oImprovement after 7
months
PASAT
Osterweil et al. [29]Y e s Improvement after 8
months
TMT(A), SDMT
Whybrow et al. [49]Y e s No change after 10.5
months
TMT(A,B)
Memory
Miller et al. [47]Y e s Improvement after 3
months
WMS, CVLT, RCFT
Burmeister et al. [42]Y e s Improvement VLT
Capet et al. [43]Y e s Improvement after 6
months
WMS, BEC-96, WMS,
Mennemeier et al. [46]Y e s
No change (but
treatment may arrest
further decline)
CVMT, FMT, RCFT, SRT, WMS
Osterweil et al. [29]Y e s Improvement IPAL
Haggerty et al. [45]Y e s Not treated WMS
Visuospatial abilities
Capet et al. [43]Y e s Improvement after 6
months
TMT(A), WAIS-R, HT
Mennemeier et al. [46]Y e sImprovement WAIS-R (BD, OAS)
Osterweil et al. [29]Y e s No improvement CC
Language (expression)
Miller et al. [47]N o No change AN
Capet et al. [43]N o No improvement
after 6 months
WFT
Mennemeier et al. [46]N oNot treated WFT
Osterweil et al. [29]Y e s No improvement WFT (Animals)
Language (reception) Osterweil et al. [29]N o Not treated WD, OR
Executive functions
Miller et al. [47]N o No change TMT(B), COWA
Mennemeier et al. [46]N oNot treated GNG, WFT, LMN
Whybrow et al. [49]Y e s No change PM
Psychomotor speed Burmeister et al. [42]N o No change WAIS-R
Capet et al. [43]Y e s Improvement after 6
months
WAIS-R, WFT, TMT(A, B)
Global cognition
Capet et al. [43]Y e s Improvement after 6
months
MMSE
Osterweil et al. [29]Y e s No improvement MMMSE
Peabody et al. [48]Y e s Progressive decline MMSECurrent Gerontology and Geriatrics Research 7
Table 5: Cognitive changes in (natural and experimental) hyperthyroidism.
Cognitive domain
Hyperthyroidism
Natural
Experimental
T3(b) T4(d) T4(e)
100μg/day 300μg/day 500μg/day
for 3 days for 21 days for 45 days
Attention Impaired(a) No change Not reported No change
Memory Impaired(a) No change Not reported No change
Visuospatial abilities Impaired(a) No change Impaired No change
Motor speed Impaired(a),(b) Not reported Not reported Not reported
No change(c)
Verbal ﬂuency No change(b) Accelerated Not reported No change
(a)Whybrow et al. [49],MacCrimmonetal.[50],Alvarezetal.[51],Trzepaczetal.[52],Toft[53]; (b)Kathman et al. [54]; (c)Zeitlhoferetal.[55]; (d)M¨ unteetal.
[56]; (e)Baethge et al. [57].
seventh decade of life. Capet et al. [43] reported that
the mean cognitive functions scores of treated patients
or controls over 70 years old tended to be lower than
those of treated patients or controls less than 60 years
o l d .O s t e r w e i le ta l .[ 29] compared cognitive performance
of a group younger than 75 years to a group over 75
years. The older group performed worse on cognitive tests
than the younger group, although there was no interaction
between age and thyroid status. In a population with a
prevalence of hypothyroidism of 14%, Luboshitzky et al.
[30] reported that global cognitive impairment increased
with age from 5.2% of the individuals aged 65–70 years
to 35.5% in the age group of 85–90 years. Thus, age may
increase vulnerability on cognitive tests to the eﬀects of
hypothyroidism.
6. Cognition Deﬁcits andHyperthyroidism
Hyperthyroid patients commonly present a variety of cog-
nitive function deﬁcits, although to a lesser degree than
in hypothyroid patients. As shown in Table 5, the most
commoncognitive deﬁcitsobserved in hyperthyroidpatients
include poorer performance on tests of attention, memory,
mental alertness, and visuomotor speed [49–53]. There are
conﬂicting results concerning eﬀects of hyperthyroidism
on motor speed [54, 55]. Treatment of hyperthyroidism is
followed by a partial return to baseline cognitive functioning
[59].
The eﬀects of experimentally raising thyroid hormones
on cognitive performance have been reported in three
studies. Increasing serum T3 levels to values within the
hyperthyroid range by administrating 100μgT 3d a i l yo v e r
3 days to 14 young, euthyroid healthy men (20–37 years
old) resulted in no signiﬁcant change in either attention,
memory, or visuomotor coordination, but a trend towards
improved verbal ﬂuency was seen [54]. Administration of
supraphysiologic doses of L-thyroxine (500μg/d for 45 days
on average) to 11 subjects (4 men, 7 women, mean age
37 years) did not change attention, memory, visuospatial
organization, verbal learning, or verbal ﬂuency [57]. In
a placebo-controlled cross-over study in 24 healthy men,
M¨ unte et al. [56] found that administration of L-thyroxine
inrelativelyhighdoses(300μgdailyfor3weeks)signiﬁcantly
improved visual processing. That cognitive functioning was
little or not changed in these short-term studies suggests that
the normal regulatory processes that modulate cognition,
and which are disturbed in clinical hyperthyroidism, are not
disrupted in healthy subjects by the use of supraphysiologic
doses of thyroid hormones.
7. Thyroid Functionand Alzheimer’s Disease
Given the potentially increased risk of cognitive decline with
thyroid dysfunction and that progressive cognitive decline
is the central clinical feature of Alzheimer’s disease, it is
possiblethatthyroidstatuscontributes,atleastinpart,tothe
clinical manifestation of Alzheimer’s disease. Several clinical
reports as well as laboratory and epidemiological studies
support a link between thyroid hormones and Alzheimer’s
pathophysiology [41, 49, 60–71]. Studies examining the rela-
tionship between TSH and Alzheimer’s disease have yielded
contradictory results. Low serum TSH concentrations as
well as high thyroxine levels were proposed as risk factors
for Alzheimer’s disease in some studies [72–74]b u tn o ti n
others [75, 76]. In a 6-year prospective follow-up study of
mild cognitive impairment (which represents a transition
between normal aging and Alzheimer’s disease), Annerbo et
al. [77] found a signiﬁcant correlation between reduced TSH
concentrations and patients converting from mild cognitive
impairment to Alzheimer’s disease. However, no signiﬁcant
correlation was found between TSH or free T4 levels and
global cognition in euthyroid patients with Alzheimer’s
disease [78].
8. Discussion
Normal thyroid function appears to be an important factor
in retaining optimal cognition in human aging [79]. Overall,
many studies suggest that there may be a continuum
characterizingtheimpactofthyroidfunctiononcognitionin
which cognitive dysfunction results from either chronically
increased or decreased concentrations of thyroid hormones.8 Current Gerontology and Geriatrics Research
Table 6: Continuum of speciﬁc cognitive defects with the degree of hypothyroidism.
Hypothyroidism status Attention Memory Speed Verbal ﬂuency Visuospatial abilities
Low normal 0/1(a) (0%) 5/6 (83%) 1/5 (20%) 1/5 (20%) 1/4 (25%)
Subclinical 2/4 (50%) 6/8 (75%) 2/5 (40%) 3/5 (60%) 0/3 (0%)
Clinical 3/5 (60%) 6/6 (100%) 1/2 (50%) 1/4 (25%) 3/3 (100%)
(a)Number of studies reporting cognitive defects over total number of studies.
For example, Table 6 shows such continuum of speciﬁc
cognitive defects with the degree of hypothyroidism. Even
thyroid hormones and TSH levels within low-normal range
appear to inﬂuence cognition performance, such that low-
normal thyroid function appears associated with cognitive
decline over time [16–18].
Many questions remain unresolved. For example, there
is disagreement as to which of TSH, T4, or T3 is the best
indicator of thyroid function, and best predictor of cognitive
decline, especially in the elderly. The relationship between
TSH and cognitive functioning appears to be inconsistent
in euthyroid elderly [15–18]. Although it is the major mod-
ulator of thyroid hormone secretion, circulating TSH may
not be a suﬃciently sensitive or direct measure of thyroid
hormone suﬃciency for brain function. Moreover, serum
TSH is inﬂuenced by a negative feedback loop associated
with thyroid hormones and by the eﬀect of other hormones
and bioactive substances, such as cortisol, somatostatin, and
cytokines [80]. TSH and cognitive performance may thus
change in parallel, possibly due to a third variable. For exam-
ple, TSH relationship with cognition may exist in a more
speciﬁc or vulnerable population, in older, lower education,
higher prevalence of cognition-related comorbidity.
Physiological studies provide support for a relationship
between T4 and cognitive processing. The brain maintains
levels of both T4 and T3 within a very narrow range, even
during important ﬂuctuations of circulating T4 [81]. Thus,
possibly, even small changes in brain T4 concentrations
could have consequences for cognitive function. Because
brain function might be negatively aﬀected by brain T4
in the lower range of normal, to function normally, the
brain of older persons might have an increased need for or
less eﬃcient capacity to access or utilize T4. The basis for
this shift could derive from aging-induced changes in T4
transportintospeciﬁcbrainregions,alteredbrainconversion
of T4 to T3, or decreased brain thyroid receptor number or
aﬃnity.
An alternative explanation may be that the apparent
paradox reﬂects diﬀerences in thyroid function before and
after a threshold around the age of 80–85 years. Indeed, an
age-dependent decline in thyroid function has been iden-
tiﬁed that is at least partially independent from associated
nonthyroidal illnesses, particularly in those older than 85
years old [82, 83]. It is thus plausible that the correlation
between cognitive decline may be stronger with T4 than
with TSH in euthyroid individuals aged between 61 and 79
years but that a positive association with TSH appears with
individuals older than 80 years old. This interpretation is
supported by the studies reporting that increasing levels of
TSHanddecreasinglevelsoffreeT4,bothrepresentinglower
thyroid function, were associated with a survival beneﬁt
[19, 82–84]. This metabolic change may reﬂect an adaptive
mechanism to preventing excessive catabolism in the oldest
elderly.
Our overall impression is that there is a substantial
degree of disagreement regarding several aspects of the
relationship between TSH, thyroid hormones, and cognitive
performance.Moststudieswereadjustedforage,educational
level, gender, and mood status, but diﬀerences in results
that remain may still be due to diﬀerences in sample
populations, exclusion criteria, age range, normal limits
of TSH reference values, and choice of cognitive tests.
Moreover, the interpretation of these results is complicated
by the coexistence of age-related nonthyroidal illnesses
which may contribute to serum thyroid hormone and TSH
perturbations but for which adequate correction may not
have been made [5, 85]. In turn, these thyroid indices
may also aﬀect cognitive performance by the degree and
the duration of hypothyroidism [23, 29, 58], by practice
eﬀects [46, 59], by the use of insuﬃcient thyroid function
indices in most studies, by the wide individual variation in
the rate at which TSH and cognitive functions deteriorate
with increasing age [17, 18], by the eﬀects of nutritional
deﬁciencies [6], or by other endocrine perturbations, such
as low sex steroids or high stress hormones, which could lead
either directly or indirectly to cognitive dysfunction [18, 86].
No consensus has been reached about the health impact
of subclinical thyroid dysfunction, for which diﬀerent
recommendations have been made about screening and
treatment [20–22, 45, 53, 87, 88]. Diﬀerent cognitive
functions clearly have diﬀerent sensitivity to hormonal or
metabolic changes and not all the cognitive defects related
t ot h y r o i df a i l u r ea r ec o m p l e t e l yr e v e r s i b l ew i t ht h y r o i d
replacement therapy.
Very few studies have examined the mechanism by which
thyroid dysfunction might inﬂuence memory performance.
T h e r ei ss o m ee v i d e n c et h a td e c r e a s e dc e r e b r a lb l o o dﬂ o wi n
mild hypothyroidism occurs in regions mediating attention,
motor speed, memory, and visuospatial processing [89].
High TSH concentrations may also decrease cerebral blood
ﬂow and glucose metabolism in clinical hypothyroidism
[90]. However, comorbid cerebrovascular disease and ele-
vated anticholinergic activity did not appear to be involved
in memory impairment in elderly individuals with a mildly
elevated serum TSH [27].
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